VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Crawford Compares Degarelix and LHRH Agonists

E. David Crawford, MD
Published: Monday, Sep 09, 2013

E. David Crawford, MD, professor in Surgery and Radiation Oncology and the head of Urologic Oncology at the University of Colorado, Anschutz Medical Campus, discusses research that led to the 2008 approval of degarelix as a treatment for men with prostate cancer.

In the pivotal study, 610 patients were randomized to receive androgen-deprivation therapy with degarelix or leuprolide. The study examined three treatment strategies. For degarelix, patients received a 240 mg subcutaneous loading dose followed by monthly maintenance therapy at 80 mg or 160 mg. For leuprolide, a 7.5 mg monthly dose was administered. The primary endpoint of suppression of testosterone levels was similar between all three dosing strategies, at the end of one year, notes Crawford.

Looking at other endpoints, the median PSA level in the degarelix groups was significantly lower than the leuprolide arm. Furthermore, Crawford notes, treatment with degarelix did not result in a testosterone flare event.

Interestingly, Crawford notes, follicle-stimulating hormone (FSH) levels were found to be higher in the leuprolide arm of the trial than with degarelix. Additionally, FSH was higher in patients treated with orchiectomy. In some situations, Crawford says, the FSH receptor is selectively expressed on the surface of blood vessels in tumors and may promote tumor growth. As a result, lowering this hormone could impact the recurrence of prostate cancer, Crawford suggests.

E. David Crawford, MD, professor in Surgery and Radiation Oncology and the head of Urologic Oncology at the University of Colorado, Anschutz Medical Campus, discusses research that led to the 2008 approval of degarelix as a treatment for men with prostate cancer.

In the pivotal study, 610 patients were randomized to receive androgen-deprivation therapy with degarelix or leuprolide. The study examined three treatment strategies. For degarelix, patients received a 240 mg subcutaneous loading dose followed by monthly maintenance therapy at 80 mg or 160 mg. For leuprolide, a 7.5 mg monthly dose was administered. The primary endpoint of suppression of testosterone levels was similar between all three dosing strategies, at the end of one year, notes Crawford.

Looking at other endpoints, the median PSA level in the degarelix groups was significantly lower than the leuprolide arm. Furthermore, Crawford notes, treatment with degarelix did not result in a testosterone flare event.

Interestingly, Crawford notes, follicle-stimulating hormone (FSH) levels were found to be higher in the leuprolide arm of the trial than with degarelix. Additionally, FSH was higher in patients treated with orchiectomy. In some situations, Crawford says, the FSH receptor is selectively expressed on the surface of blood vessels in tumors and may promote tumor growth. As a result, lowering this hormone could impact the recurrence of prostate cancer, Crawford suggests.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x